76 studies found for:    visilizumab
Show Display Options
Rank Status Study
1 Terminated Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
Condition: Ulcerative Colitis
Intervention: Drug: Visilizumab
2 Terminated
Has Results
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Condition: Graft Versus Host Disease
Interventions: Drug: Visilizumab;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Antithymocyte globulin (ATG)
3 Terminated A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: visilizumab
4 Completed Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
Condition: Severe Ulcerative Colitis
Intervention: Drug: Visilizumab
5 Terminated An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: Visilizumab (Nuvion®; HuM291)
6 Unknown  Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects
Condition: Chronic Hepatitis C
Interventions: Drug: anti-CD3 monoclonal antibody;   Drug: Sodium Chloride placebo
7 Terminated Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
Condition: Ulcerative Colitis
Intervention: Drug: visilizumab
8 Completed Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: Visilizumab
9 Completed
Has Results
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: Anti-CD3 mAb;   Other: Diabetes Standard of Care Treatment;   Dietary Supplement: Iron supplementation
10 Completed Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: Visilizumab
11 Withdrawn A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Condition: Intravenous Steroid-Refractory Ulcerative Colitis
Intervention: Drug: Visilizumab (HuM291; Nuvion®)
12 Completed Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome
Condition: Nonalcoholic Steatohepatitis
Intervention: Drug: OKT3
13 Completed Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: Visilizumab
14 Unknown  Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
Condition: Graft-vs-Host Disease
Intervention: Drug: Visilizumab
15 Unknown  Oral OKT3 in Combination With Beta-D-Glucosylceramide
Condition: Healthy
Interventions: Drug: OKT3;   Drug: OKT3, GC;   Drug: GC
16 Withdrawn Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease
Condition: Acute Graft Versus Host Disease
Intervention: Biological: IT-Combination
17 Completed Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
Conditions: Ovarian Cancer;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Intervention: Biological: anti-EpCAM x anti-CD3 (removab)
18 Completed Research Study in Patients With Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: Visilizumab
19 Completed Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
20 Completed Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma
Conditions: Lymphoma;   Small Intestine Cancer
Intervention: Biological: visilizumab

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years